Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model

Immunobiology

Volumn 218, Issue 6, 2013, Pages 851-859

  Rosalia, Rodney A ^a,b   Štěpánek, Ivan ^a   Polláková, Veronika ^a   Šímová, Jana ^a   Bieblová, Jana ^a   Indrová, Marie ^a   Moravcová, Simona ^a   Přibylová, Hana ^a   Bontkes, Hetty J ^b   Bubeník, Jan ^a   Sparwasser, Tim ^c   Reiniš, Milan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Cancer immunotherapy; DEREG mice; Interferon ; Natural killer T cells; PC61 monoclonal antibody; T regulatory cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 4; MONOCLONAL ANTIBODY; PC61 ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; EFFECTOR CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD1D; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GALACTOSYLCERAMIDES; GENE EXPRESSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NATURAL KILLER T-CELLS; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN;

EID: 84876303665     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.10.012     Document Type: Article

References (47)

1. + Treg during sensitization phase aggravates experimental allergic airway inflammation. Eur. J. Immunol. 2010, 40:2259-2266.
2. Bessoles S., Fouret F., Dudal S., Besra G.S., Sanchez F., Lafont V. IL-2 triggers specific signaling pathways in human NKT cells leading to the production of pro- and anti-inflammatory cytokines. J. Leukoc. Biol. 2008, 84:224-233.
3. Burdin N., Brossay L., Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur. J. Immunol. 1999, 29:2014-2025.
4. Chang Y.J., Huang J.R., Tsai Y.C., Hung J.T., Wu D., Fujio M., et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc. Natl. Acad. Sci. U.S.A. 2007, 25:10299-10304.
5. Couper K.N., Lanthier P.A., Perona-Wright G., Kummer L.W., Chen W., Smiley S.T., et al. Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection. J. Immunol. 2009, 182:3985-3994.
6. Crowe N.Y., Uldrich A.P., Kyparissoudis K., Hammond K.J., Hayakawa Y., Sidobre S., et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J. Immunol. 2003, 171:4020-4027.
7. Curtin J.F., Candolfi M., Fakhouri T.M., Liu C., Alden A., Edwards M., et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE 2008, 4:1983.
8. Fujii S., Shimizu K., Smith C., Bonifaz L., Steinman R.M. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 2003, 198:267-279.
9. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., Van Kaer L. NKT cells: what's in a name?. Nat. Rev. Immunol. 2004, 4:231-237.
10. + regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. Clin. Exp. Immunol. 2010, 159:93-99.
11. Ikarashi Y., Iizuka A., Koshidaka Y., Heike Y., Takaue Y., Yoshida M., et al. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide. Immunology 2006, 116:30-37.
12. Kim H.Y., Kim S., Chung D.H. FcgammaRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation. J. Clin. Invest. 2006, 116:2484-2492.
13. + regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010, 70:7788-7799.
14. + regulatory T cells. J. Exp. Med. 2005, 202:885-891.
15. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 2005, 23:877-900.
16. + Tregs and NKT cells: regulators regulating regulators. Trends Immunol. 2006, 7:322-327.
17. + regulatory T cells induces a scurfy-like disease. J. Exp. Med. 2007, 204:57-63.
18. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumours with a novel vaccine that enhances major histocompatibility class II presentation of tumour antigen. Cancer Res. 1996, 56:21-26.
19. + T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 2005, 12:7898-7904.
20. + regulatory T cells. J. Immunol. 2006, 6:3695-3704.
21. Malek T.R., Robb R.J., Shevach M.J. Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:5694-5698.
22. Miyamoto K., Miyake S., Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature 2001, 413:531-534.
23. Miyara M., Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 2007, 13:108-116.
24. Moreno M., Molling J.W., von Mensdorff-Pouilly S., Verheijen R.H., von Blomberg B.M., van den Eertwegh A.J., et al. In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells. Clin. Immunol. 2008, 1:145-154.
25. Motoyoshi Y., Kaminoda K., Saitoh O., Hamasaki K., Nakao K., Ishii N., et al. Different mechanisms for anti-tumour effects of low- and high-dose cyclophosphamide. Oncol. Rep. 2006, 16:141-146.
26. Nakagawa R., Serizawa I., Motoki K., Sato M., Ueno H., Iijima R., et al. Antitumor activity of alpha-galactosylceramide. KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumour infiltrating cells. Oncol. Res. 2000, 2:51-58.
27. Nishikawa H., Sakaguchi S. Regulatory T cells in tumour immunity. Int. J. Cancer 2010, 127:759-767.
28. + regulatory T cells: control of FOXP3 expression by pharmacological agents. Trends Pharmacol. Sci. 2011, 32:158-166.
29. Parekh V.V., Wilson M.T., Olivares-Villagómez D., Singh A.K., Wu L., Wang C.R., et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 2005, 115:2572-2583.
30. Petersen T.R., Sika-Paotonu D., Knight D.A., Dickgreber N., Farrand K.J., Ronchese F., et al. Potent anti-tumour responses to immunization with dendritic cells loaded with tumour tissue and an NKT cell ligand. Immunol. Cell Biol. 2010, 88:596-604.
31. Ramakers C., Ruijter J.M., Deprez R.H., Moorman A.F. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci. Lett. 2003, 339:62-66.
32. + regulatory T cells in self-tolerance and autoimmune disease. Curr. Top. Microbiol. Immunol. 2006, 305:51-66.
33. + regulatory T-cells for the augmentation of cancer immunotherapy. Curr. Opin. Investig. Drugs 2007, 8:1002-1008.
34. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 2006, 7:1693-1700.
35. Seino K., Fujii S., Harada M., Motohashi S., Nakayama T., Fujisawa T., et al. Valpha14 NKT cell-mediated anti-tumour responses and their clinical application. Springer Semin. Immunopathol. 2005, 1:65-74.
36. Silk J.D., Hermans I.F., Gileadi U., Chong T.W., Shepherd D., Salio M., et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J. Clin. Invest. 2004, 114:1800-1811.
37. Símová J., Bubeník J., Bieblová J., Rosalia R.A., Fric J., Reinis M. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours. Int. J. Oncol. 2006, 6:1567-1571.
38. Símová J., Indrová M., Bieblová J., Mikysková R., Bubeník J., Reinis M. Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy. Int. J. Cancer 2010, 126:2997-3004.
39. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 6:655-669.
40. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004, 12:3804-3812.
41. Tenorio E.P., Fernández J., Olguín J.E., Saavedra R. Depletion with PC61 mAb before Toxoplasma gondii infection eliminates mainly Tregs in BALB/c mice, but activated cells in C57BL/6J mice. FEMS Immunol. Med. Microbiol. 2011, 62:362-367.
42. Thèze J., Alzari P.M., Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol. Today 1996, 17:481-486.
43. Thompson C., Powrie F. Regulatory T cells. Curr. Opin. Pharmacol. 2004, 4:408-414.
44. + regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 46:18169-18174.
45. Wesley J.D., Tessmer M.S., Chaukos D., Brossay L. NK cell-like behavior of Valpha14i NK T cells during MCMV infection. PLoS Pathog 2008, 4e:1000106.
46. Yu K.O., Im J.S., Molano A., Dutronc Y., Illarionov P.A., Forestier C., et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:3383-3388.
47. + cells unmasks tumour immunogenicity leading to the rejection of late-stage tumours. J. Exp. Med. 2005, 201:779-791.